ABSTRACT Corticosteroids may produce mood changes. This could account for improvement in patients with chronic airflow limitation following trials of oral corticosteroid treatment as mood elevation might improve performance in objective measurements. This proposition was tested in 21 patients with chronic airflow limitation, who underwent detailed psychological assessment during a randomised controlled double blind crossover trial of the effect of prednisolone 40 mg daily compared with that of a placebo. Self rating visual analogue scales for various qualities of mood were completed before the study and after each phase in addition to depression and psychological symptom questionnaires. After treatment with the placebo, patients showed increases in cheerfulness (p < 0.01) and sociability (p < 0.01) and a decrease in depression (p <0.01). After treatment with prednisolone there were increases in cheerfulness (p < 0.01), optimism (p < 0.01), activity (p < 0.05), and sociability (p < 0.02) and there was a decrease in depression (p < 0.01). When placebo and prednisolone values were compared, however, there were no significant differences. Some patients showed improvements (>20%) in peak expiratory flow, FEV, or forced vital capacity (FVC) after prednisolone, but nearly all had improvements in at least one psychological test. There were no detectable associations between changes in objective measurements and changes in psychological test ratings. This study suggests that in patients with chronic obstructive lung disease significant psychological changes are no more likely to follow treatment with a corticosteroid than treatment with a placebo and that physiological improvement after corticosteroid treatment is not tied to psychological changes. 
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Progressive chronic airflow limitation is a common clinical problem and a short course of high dose corticosteroids is often tried when other measures fail to control progression of symptoms and disability. Many studies of the effects of treatment with oral corticosteroid drugs in patients with chronic airflow limitation have now been reported,' but the precise role of the treatment remains uncertain.
Many studies have claimed demonstrable objective benefit from corticosteroids,2-6 although this is not universal.78 No previous study has examined the role of psychological changes in improvement following oral corticosteroid treatment.
It is well known, although difficult to prove conclusively,9 that corticosteroids alter mood. Both (1) (2) (3) (4) (5) and the oxygen cost diagram.'2 Each patient completed a 10 cm visual analogue line self assessment rating for feelings of general well being. Arterial blood gases tensions were measured at rest. Exercise performance was assessed on the basis of the 12 minute walking distance,'2 and a perceived exertion rating'3 was obtained after the walk. Each patient did a practice walk several hours before the baseline 12 minute walk. Peak expiratory flow (PEFR), FEV, and FVC were measured before and after inhalation of 200 gg salbutamol aerosol. All measurements were made at the same time of day for each patient before routine bronchodilators had been taken. TLC was measured by body plethysmography.
The following psychological measurements were made. Mood was assessed by means of self rating 10 cm analogue lines'4 recording separately cheerfulness, optimism, speed of thought, activity, and sociability. Scores of these five qualities were summed to produce a "euphoria rating." Analogue lines were also used to record sex drive, anxiety, and depression. Each patient completed the 20 item General Health Questionnaire,'5 which is a screening assessment of current psychological symptoms, and the Wakefield self administered depression inventory. ' It is well known that corticosteroid treatment may produce psychological changes,9 particularly in doses of greater than 40 mg prednisolone a day.'0 Nevertheless, in a large controlled study of patients taking corticosteroids (20 mg or less of prednisolone/day) for various respiratory diseases there was no increased incidence of psychosis in the treated group.20 A recent study2' of 39 patients with neuromuscular disorders having corticosteroid treatment showed that they had less emotional disorder than a well matched group of 33 similar patients attending the same clinic who were not having such treatment. This might support the view that corticosteroids are euphoriant, but no measure of euphoria was made.
In the present study it could be argued that psychological changes were not seen because of the small number of patients studied. We feel, however, that if the commonly observed improvement in chronic airflow limitation with steroid treatment is due to the euphoriant effect there should have been more improvement in the prednisolone group in this study as some patients did improve physiologically.
Our study has shown that there is no correlation between psychological state and severity of disability or treatment response. A considerable placebo benefit was seen both in objective measurements and in psychological state. Prednisolone had no effect on psychological state over and above the placebo effect. We conclude that steroids do not produce benefit in chronic airflow limitation by a non-specific euphoriant effect. 
